Evidence map›Paper›PMID 39273697›Full record

ArticleInternational journal of molecular sciences2024

The Impact of

Dzastina Cebatoriene, Alvita Vilkeviciute, Greta Gedvilaite-Vaicechauskiene, Monika Duseikaite, Akvile Bruzaite, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Sex- and age-specific associations ofAnnals of medicine · 2026
    Article
  2. Review
  3. Review
  4. EvaluatingMedicina (Kaunas, Lithuania) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dzastina CebatorieneMedical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus St. 9, LT-44307 Kaunas, Lithuania.
Alvita VilkeviciuteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.ORCID 0000-0002-0427-5568
Greta Gedvilaite-VaicechauskieneNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
Monika DuseikaiteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
Akvile BruzaiteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.ORCID 0009-0005-6654-8575
Loresa KriauciunieneNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
Dalia ZaliunieneDepartment of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
Rasa LiutkevicieneNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.ORCID 0000-0001-5395-923X

Funding

Research Council of Lithuania under the initiative of Re-searcher Group Projects. S-MIP-23-96
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a major global health problem as it is the leading cause of irreversible loss of central vision in the aging population. Anti-vascular endothelial growth factor (anti-VEGF) therapies are effective but do not respond optimally in all patients. This study investigates the genetic factors associated with susceptibility to AMD and response to treatment, focusing on key polymorphisms in the

Indexed as

Interleukin-1betaMacular DegenerationPolymorphism, Single NucleotideReceptors, Tumor Necrosis Factor, Type IVascular Endothelial Growth Factor AAgedAged, 80 and overAllelesFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedProteinsReceptors, Tumor Necrosis Factor, Type IIARMS2 protein, humanIL1B protein, humanInterleukin-1betaProteinsReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITNFRSF1A protein, humanTNFRSF1B protein, humanVascular Endothelial Growth Factor AVEGFA protein, humanage-related macular degenerationanti-VEGF therapyARMS2ARMS2 (rs10490924)ELISAgene polymorphismsIL1B1IL1B1 (rs1143623)TNFRSF1ATNFRSF1A (rs4149576)TNFRSF1BTNFRSF1B (rs1061622)VEGFAVEGFA (rs3024997)

Identifiers

PMID39273697
PMCPMC11396313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.